About
Christian Hein
Independent executive advisor on artificial intelligence and digital transformation in healthcare. Based in Zurich. Working with life science leadership, techbio and healthtech founders, investors, and accelerator programs.
Background
Twenty years inside large pharma, most recently as Vice President for Digital Transformation at Novartis, before stepping out to advise full-time. Earlier in the trajectory: commercial strategy, market access, business development, regulatory, and innovation management across Switzerland, Germany, France, the United States, China, Russia, and the Middle East.
Educated at the École Supérieure de Biotechnologie de Strasbourg. Working languages: English, German, French.
What the advisory work covers
- AI strategy for life sciences executives, with emphasis on what actually compounds versus what is performative.
- Agentic transformation programs at the C-suite level, especially where the work meets a real P&L rather than a slide deck.
- Working with investors on due diligence, board roles, and strategic partnerships/go-to-market support for the portfolio.
- Bridging large pharma constraints with biotech and tech-bio ambition without losing what each side actually optimizes for.
Selected essays
A short starting shelf for the recurring arguments behind the advisory work.
- Three things I watch when reading any pharma AI announcement in 2026 — Capital depth, role mix, and integration target. Three signals that separate a real pharma AI capability build from a press-release pilot dressed up as a strategic partnership.
- OpenAI in pharma: Novo Nordisk, GPT-Rosalind, and the life sciences platform play — Last week, OpenAI made two moves in pharma within 48 hours — a flagship enterprise deal with Novo Nordisk and the launch of GPT-Rosalind — and the sequencing tells a deliberate story about how they're building a verticalised commercial infrastructure for life sciences. Having sat on the pharma buyer side, I break down what that cadence actually accomplishes.
- Lab-in-the-loop drug discovery is an operating model problem, not a model problem — Lab-in-the-loop gets talked about like it’s a model problem. The Roche/Novartis/Microsoft panel at health.tech | global summit Basel made the real point clearer: it’s an operating model problem. Most orgs are at Level 1–2 maturity, and that’s already useful — the first big value isn’t more hits, it’s faster, more confident kill decisions.
- OpenEvidence exits Europe: what AI Act uncertainty means for clinical AI — OpenEvidence has withdrawn from the EU and UK citing regulatory uncertainty around the EU AI Act, making the geography of clinical AI access officially American. I break down what this means for US and European pharma, and why the AI Act's first observable market effect may be pushing physicians toward less-grounded AI alternatives.
- Clinical LLM benchmarks: why SNOMED CT mapping is a real-world test — The AI-in-healthcare debate keeps swinging between “AI is going to take over everything” and “AI is useless in a medical setting.” Neither is useful. What the field actually needs are external neutral benchmarks on specific clinical tasks. Congrats to Rory Davidson and team for bringing one to market.
- Europe’s pharma AI risk: value capture matters more than headcount — Europe keeps asking “will AI in pharma R&D mean fewer jobs?” That’s the wrong question. The right one is who captures the value. Adoption is real but structurally slow. TechBio reshapes the pipeline economy. Data hunger grows. The real risk: while Europe debates headcount, the platforms and IP get built elsewhere.
Selected public references
A small set of public sources for current roles, governance work, interviews, and writing.
- SNOMED International — Management Board profile covering pharma leadership, health AI advisory work, and board appointment.
- QuantHealth — Advisory Board role with an AI-driven clinical trial simulation company.
- health.tech — Program Advisory Board profile for healthtech, AI, Novartis scaling work, SNOMED, QuantHealth, and Vorwerk Ventures.
- Kickstart Innovation — Community advisor profile for CH Health Tech Advisory.
- DayOne — Published advice for HealthTech startups on partnering with pharma, including AI scaling background.
- Healthcare IT News — Interview on why smaller health technology companies need partnerships to scale AI in healthcare.
- CH Health Tech Insights — Current writing on AI, pharma, healthtech, TechBio, governance, and adoption.
- LinkedIn — Current professional profile and ongoing public commentary.
Selected speaking and panels
A deliberately short set of public speaking references, focused on AI in healthcare and healthtech.
- Health Tech Forward — 2025 speaker profile for Health Tech Forward Barcelona, including HealthTech, AI, and venture advisory background.
- WHX Dubai — WHX in Dubai 2026 speaker profile in the official WHX Events app.
- World Health Expo Insights — Panel write-up and quoted commentary on generative AI in healthcare from WHX Tech-EHS Summit Dubai.
Press
- Handelsblatt — AI in pharma R&D and European AI strategy
- Swissinfo — Roche's AI supercomputer and pharma AI infrastructure
How to reach me
The fastest path is LinkedIn. For longer correspondence, read what I am writing first — most conversations start there.